VERNIERI, CLAUDIO
VERNIERI, CLAUDIO
Dipartimento di Oncologia ed Emato-Oncologia
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study
2017 C. Vernieri, M. Milano, A. Mennitto, C. Maggi, B. Ferrari, L. Rinaldi, R. Mennitto, C. Stefanetti, B. Re, G. Mariani, G. Bianchi, G. Capri, F. de Braud
Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters
2021 C. Borreani, S. Alfieri, G. Infante, R. Miceli, P. Mariani, M. Bosisio, C. Vernieri, G.V. Bianchi, G. Capri
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
2020 E. Zattarin, C. Fabbroni, F. Ligorio, A. Marra, C. Corti, O. Bernocchi, M. Sirico, D. Generali, G. Curigliano, G. Bianchi, G. Capri, L. Rivoltini, F. De Braud, C. Vernieri
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders
2020 W.-. Kong, C. Vernieri, M. Foiani, J.-. Jiang
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
2022 E. Zattarin, F. Nichetti, F. Ligorio, L. Mazzeo, R. Lobefaro, G. Fuca, G. Peverelli, A. Vingiani, G. Bianchi, V, G. Capri, F. de Braud, C. Vernieri
Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process
2018 P. Bonaiuti, E. Chiroli, F. Gross, A. Corno, C. Vernieri, M. Štefl, M. Cosentino Lagomarsino, M. Knop, A. Ciliberto
Combination of baseline LDH, performance status and age as integrated algorithm to identify solid tumor patients with higher probability of response to anti PD-1 and PD-l1 monoclonal antibodies
2019 M.S. Cona, M. Lecchi, S. Cresta, S. Damian, M. Del Vecchio, A. Necchi, M.M. Poggi, D. Raggi, G. Randon, R. Ratta, D. Signorelli, C. Vernieri, F. de Braud, P. Verderio, M. Di Nicola
Diet and supplements in cancer prevention and treatment : clinical evidences and future perspectives
2018 C. Vernieri, F. Nichetti, A. Raimondi, S. Pusceddu, M. Platania, F. Berrino, F. de Braud
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
2017 D. Oddo, G. Siravegna, A. Gloghini, C. Vernieri, B. Mussolin, F. Morano, G. Crisafulli, R. Berenato, G. Corti, C.C. Volpi, M. Buscarino, M. Niger, P.D. Dunne, G. Rospo, E. Valtorta, A. Bartolini, G. Fucà, S. Lamba, A. Martinetti, M. Di Bartolomeo, F. De Braud, A. Bardelli, F. Pietrantonio, F. Di Nicolantonio
Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis
2021 A. Ajazi, C. Bruhn, G. Shubassi, C. Lucca, E. Ferrari, A. Cattaneo, A. Bachi, N. Manfrini, S. Biffo, E. Martini, S. Minucci, C. Vernieri, M. Foiani
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma : the FAME Trial
2019 C. Vernieri, D. Signorelli, G. Galli, M. Ganzinelli, M. Moro, A. Fabbri, E. Tamborini, M. Marabese, E. Caiola, M. Broggini, L. Hollander, R. Gallucci, G. Vandoni, C. Gavazzi, T. Triulzi, M.P. Colombo, A.M. Rizzo, P.A. Corsetto, G. Pruneri, F. de Braud, G. Sozzi, V. Torri, M.C. Garassino
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer
2017 F. Pietrantonio, C. Vernieri, G. Siravegna, A. Mennitto, R. Berenato, F. Perrone, A. Gloghini, E. Tamborini, S. Lonardi, F. Morano, B. Picciani, A. Busico, C.C. Volpi, A. Martinetti, F. Battaglin, I. Bossi, A. Pellegrinelli, M. Milione, C. Cremolini, M. Di Bartolomeo, A. Bardelli, F. De Braud
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
2020 E. Zattarin, R. Leporati, F. Ligorio, R. Lobefaro, A. Vingiani, G. Pruneri, C. Vernieri
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
2016 S. Pusceddu, F. De Braud, G. Lo Russo, L. Concas, D. Femia, C. Vernieri, A. Indini, B. Formisano, R. Buzzoni
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 C. Vernieri, F. Nichetti, L. Lalli, L. Moscetti, C.A. Giorgi, G. Griguolo, A. Marra, G. Randon, C.G. Rea, F. Ligorio, S. Scagnoli, C. De Angelis, C. Molinelli, A. Fabbri, E. Ferraro, D. Trapani, A. Milani, E. Agostinetto, O. Bernocchi, G. Catania, A. Vantaggiato, M. Palleschi, A. Moretti, D. Basile, M. Cinausero, A. Ajazi, L. Castagnoli, S. Lo Vullo, L. Gerratana, F. Puglisi, N. La Verde, G. Arpino, A. Rocca, M. Ciccarese, R. Pedersini, A. Fabi, D. Generali, A. Losurdo, F. Montemurro, G. Curigliano, L. Del Mastro, A. Michelotti, E. Cortesi, V. Guarneri, G. Pruneri, L. Mariani, F. de Braud
Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)
2019 C. Vernieri, S. Pusceddu, G. Fucà, P. Indelicato, G. Centonze, L. Castagnoli, E. Ferrari, A. Ajazi, S. Pupa, S. Casola, M. Foiani, V. Mazzaferro, G. Pruneri, M. Milione, F. de Braud
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting
2018 F. De Santis, M. Del Vecchio, L. Castagnoli, F. De Braud, S. Di Cosimo, D. Franceschini, G. Fucà, J. Hiscott, K.J. Malmberg, N. Mcgranahan, F. Pietrantonio, L. Rivoltini, S. Sangaletti, E. Tagliabue, C. Tripodo, C. Vernieri, L. Zitvogel, S.M. Pupa, M. Di Nicola
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC
2018 M. Moro, E. Caiola, M. Ganzinelli, E. Zulato, E. Rulli, M. Marabese, G. Centonze, A. Busico, U. Pastorino, F. de Braud, C. Vernieri, M. Simbolo, E. Bria, A. Scarpa, S. Indraccolo, M. Broggini, G. Sozzi, M. Garassino
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
2018 S. Pusceddu, C. Vernieri, M. Di Maio, R. Marconcin, F. Spada, S. Massironi, T. Ibrahim, M. Brizzi, D. Campana, A. Faggiano, D. Giuffrida, M. Rinzivillo, S. Cingarlini, F. Aroldi, L. Antonuzzo, R. Berardi, L. Catena, C. De Divitiis, P. Ermacora, V. Perfetti, A. Fontana, P. Razzore, C. Carnaghi, V. Maria, C. Cauchi, M. Duro, S. Sergio, N. Fazio, F. Cavalcoli, A. Bongiovanni, A. La Salvia, N. Brighi, A. Colao, I. Puliafito, F. Panzuto, S. Ortolani, A. Zaniboni, F. Di Costanzo, M. Torniai, E. Bajetta, S. Tafuto, S. Garattini, D. Femia, N. Prinzi, L. Concas, G. Lo Russo, M. Milione, L. Giacomelli, R. Buzzoni, G. Delle Fave, V. Mazzaferro, F. de Braud
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes
2016 S. Pusceddu, R. Buzzoni, C. Vernieri, L. Concas, S. Marceglia, L. Giacomelli, M. Milione, L. Leuzzi, D. Femia, B. Formisano, V. Mazzaferro, F. De Braud